News

Q2 2023 Newsletter – acyl glucuronides, hydroxylated metabolites and latest blogs

Hypha’s Q2 2023 Newsletter – acyl glucuronides, hydroxylated metabolites and our latest blogs

In our Q2 2023 newsletter we look at the synthesis of a prominent acyl glucuronide of the Mcl-1 inhibitor AZD5991, hydroxylated metabolites of the recently FDA approved rezafungin, as well as links to our latest blogs.

More News

Metabolites that Matter – Ivermectin

Metabolites that Matter – Ivermectin Ivermectin is a natural product derived broad spectrum antiparasitic drug, primarily deployed to combat parasitic worms in veterinary and human

Molecules that Matter – Rezafungin

Molecules that Matter – Rezafungin Rezafungin is an echinocandin with a chemical modification that confers high stability, a longer half-life, and allows for a once-a-week

Q1 2023 Newsletter – Recombinant metabolising enzymes

Hypha’s Q1 2023 newsletter – Recombinant metabolising enzymes In our Q1 2023 newsletter we focus on Hypha’s recombinant enzymes, in particular new innovations to our

Ready to begin? Our scientists are available to talk through your requirements

Hypha Discovery is a UK-based CRO supporting pharmaceutical and agrochemical companies worldwide through the production of metabolites and new derivatives of drugs and agrochemicals in discovery and development.

News

Q2 2023 Newsletter – acyl glucuronides, hydroxylated metabolites and latest blogs

Hypha’s Q2 2023 Newsletter – acyl glucuronides, hydroxylated metabolites and our latest blogs

More News

Metabolites that Matter – Ivermectin

Molecules that Matter – Rezafungin

Q1 2023 Newsletter – Recombinant metabolising enzymes

Ready to begin? Our scientists are available to talk through your requirements

What We Do

Our Products

Our Science

Resources

Don't forget to subscribe to our newsletter and blog!